<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03676569</url>
  </required_header>
  <id_info>
    <org_study_id>17/2014 IMiD</org_study_id>
    <nct_id>NCT03676569</nct_id>
  </id_info>
  <brief_title>Intrathecal Autologous ADRC Treatment of Autoimmune Refractory Epilepsy</brief_title>
  <acronym>EPIMSC</acronym>
  <official_title>Intrathecal Autologous Adipose Derived Regenerative Cells Treatment of Autoimmune Determined Refractory Epilepsy - Evaluation of Safety and Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mossakowski Medical Research Centre Polish Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Mother and Child, Warsaw, Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mossakowski Medical Research Centre Polish Academy of Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Refractory epilepsies caused by an autoimmune mechanisms lead in children to progressive&#xD;
      neurodegeneration. Immunomodulation therapy is effective only in a half of such cases. New&#xD;
      approaches are undertaken. It was found that ADRC (adipose derived regenerative cells)&#xD;
      isolated from adipose tissue consist mesenchymal stem cells that act as tissue repair cells.&#xD;
      The purpose of this experimental study is to evaluate the possibility and safety of the use&#xD;
      of multipotent mesenchymal adipose derived regenerative cells (ADRC) in patients diagnosed&#xD;
      with an autoimmune determined refractory epilepsy.&#xD;
&#xD;
      Study protocol:&#xD;
&#xD;
      Intrathecal infusions of autologous ADRC obtained after liposuction followed by isolation by&#xD;
      Cytori system will be performed. Procedure will be repeated 3 times every 3 months in each&#xD;
      patient. Neurological status, brain MRI, cognitive function and antiepileptic effect will be&#xD;
      supervised during 24 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epilepsy is a chronic neurological disorder diagnosed in about 1% of the population, or c.&#xD;
      400,000 patients in Poland. Autoimmune refractory epilepsy is rare but most disabled epilepsy&#xD;
      leading to developmental regression. The belief in a positive effect of ADRCs in&#xD;
      drug-resistant epilepsy comes from test results showing the ability of mesenchymal cells to&#xD;
      concentrate in damaged tissues, as well as their strong immunomodulating, especially&#xD;
      anti-inflammatory, properties. Patients with drug resistant epilepsy show decreased numbers&#xD;
      of neurons within the epilepsy zone, with most of these being hyperactive and malfunctioning.&#xD;
      Additionally, an inflammatory active reaction in affected brain tissue is visible.&#xD;
      ADRC-induced activation of endogenous neurogenesis may increase chances that the epilepsy&#xD;
      zone will be reduced, and give a positive impact as regards the neuropsychiatric disorders&#xD;
      commonly present in patients with epilepsy. Another common process accompanying recurring&#xD;
      epilepsy attacks is active inflammation. Per the literature, ADRCs show strong&#xD;
      neuroprotective, immunomodulating and antiapoptotic qualities and they may potentially reduce&#xD;
      the frequency of epilepsy attacks. Thus, a clinical trial with ADRCs, addressed to&#xD;
      drug-resistant epilepsy sufferers would be promising in controlling the epileptic seizures&#xD;
      and coexisting behavioral / psychiatric symptoms. The goal is to improve the quality of life&#xD;
      of the patients and their caregivers.&#xD;
&#xD;
      In patients who were diagnosed with autoimmune drug-resistant epilepsy and have met the set&#xD;
      criteria and qualified to take part in the examination, after a formal written consent of&#xD;
      their parents at the Clinic of Child Neurology IMC neurological examination, routine&#xD;
      laboratory tests, EEG and neuropsychological assessment will be performed. ADRC will be&#xD;
      obtained after liposuction and isolation with Cytori system.&#xD;
&#xD;
      Before intrathecal transplantation of ADRC suspension ( 5 ml), cerebrospinal fluid will be&#xD;
      collected for evaluation of origin protein level, oligoclonal bands, the IgG index as well as&#xD;
      GluR3, VGKC complex/LGI1, GM1, NT-3, GAD, and NMDAR antibodies. At the same time there will&#xD;
      be an intake of 5ml of serum to evaluate levels of immunoglobulins IgA, IgM and IgG.&#xD;
&#xD;
      Procedure will be repeated 3 times every 3 months in each patient. Neurological status, brain&#xD;
      MRI, cognitive function and antiepileptic effect will be supervised during 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 15, 2015</start_date>
  <completion_date type="Actual">April 14, 2019</completion_date>
  <primary_completion_date type="Actual">April 14, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Experimental clinical treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of epileptic seizures</measure>
    <time_frame>3 months</time_frame>
    <description>recording of epileptic seizures frequency, EEG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intelligence test</measure>
    <time_frame>3 months</time_frame>
    <description>The Leiter contains 10 subtests organized into four domains: Fluid Intelligence Visualization, Memory, Attention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>School progress</measure>
    <time_frame>3 months</time_frame>
    <description>teacher references</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Radiological assesment</measure>
    <time_frame>12 months</time_frame>
    <description>MRI</description>
  </other_outcome>
  <other_outcome>
    <measure>The level of antineural antibodies</measure>
    <time_frame>3 months</time_frame>
    <description>protein level, oligoclonal bands, IgG index as well as GluR3, VGKC complex/LGI1, GM1, NT-3, GAD, NMDAR antibodies from cerebrospinal fluid for evaluation the origin</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Refractory Epilepsy</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous ADRC transplantation in autoimmune refractory epilepsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ADRC transplantation in autoimmune refractory epilepsy</intervention_name>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Drug-resistant epilepsy confirmed in anamnesis and diagnostic tests (EEG, MR)&#xD;
&#xD;
          -  Children between 3 and 18 years old&#xD;
&#xD;
          -  Presence of antineuronal antibody in serum or CSF&#xD;
&#xD;
          -  Rasmussen encephalitis (proven cellular immunity pathogenesis)&#xD;
&#xD;
          -  Probable autoimmune pathogenesis (autoimmune diseases in family, febrile infection&#xD;
             associated refractory epilepsy)&#xD;
&#xD;
          -  Willing and able to provide written informed consent (patient or legal guardian)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refractory epilepsy with proven genetic or metabolic ethiology&#xD;
&#xD;
          -  Neoplastic disease&#xD;
&#xD;
          -  Active inflammatory process at the time of recruitment&#xD;
&#xD;
          -  Coagulation disorder&#xD;
&#xD;
          -  Status epilepticus&#xD;
&#xD;
          -  Participation in another clinical trial&#xD;
&#xD;
          -  Lack of willingness and ability to provide written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorota Antczak-Marach, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Mother and Child</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ewa Sawicka, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Mother and Child</affiliation>
  </overall_official>
  <results_reference>
    <citation>Szczepanik E, Mierzewska H, Antczak-Marach D, Figiel-Dabrowska A, Terczynska I, Tryfon J, Krzesniak N, Noszczyk BH, Sawicka E, Domanska-Janik K, Sarnowska A. Intrathecal Infusion of Autologous Adipose-Derived Regenerative Cells in Autoimmune Refractory Epilepsy: Evaluation of Safety and Efficacy. Stem Cells Int. 2020 Jan 3;2020:7104243. doi: 10.1155/2020/7104243. eCollection 2020.</citation>
    <PMID>32190059</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 14, 2018</study_first_submitted>
  <study_first_submitted_qc>September 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mossakowski Medical Research Centre Polish Academy of Sciences</investigator_affiliation>
    <investigator_full_name>Anna Sarnowska</investigator_full_name>
    <investigator_title>M.D., Ph.D.; Head of Translative Platform for Regenerative Medicine MRC Mossakowski PAS</investigator_title>
  </responsible_party>
  <keyword>autoimmune epilepsy</keyword>
  <keyword>refractory epilepsy</keyword>
  <keyword>ADRC</keyword>
  <keyword>mezenchymal stem cells</keyword>
  <keyword>anti-neuronal antibody</keyword>
  <keyword>Rasmussen encephality</keyword>
  <keyword>adipose derived regenerative stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

